One dose, no titration

GEMTESA (vibegron) is the first and only beta-3 agonist that offers your patients1:

  • One 75 mg dose with no titration to be taken daily with or without food and swallowed whole with
    a glass of water1

  • One crushable pill In adults, GEMTESA tablets may be crushed, mixed with a tablespoon
    (~15 mL) of applesauce and taken immediately with a glass of water1

GEMTESA® pill bottle.

Interested in prescribing GEMTESA? Request samples for your patients

Click below to request samples or request a live or virtual
visit with a GEMTESA representative.

Request samples

Request a rep

You and your patients can work together to help ensure they
get the overactive bladder (OAB) medication you have chosen

Healthcare professional

Consider the following, where appropriate,
for patients who are having trouble filling prescriptions:

  • DAW (dispense as written)*
  • Medically necessary
  • Brand only

*Follow your state's required language or special instructions.

Patient or caregiver

May consider the following to communicate with the pharmacy:

  • Request no substitutions before the medication is dispensed
  • Verify they have received GEMTESA
  • Discuss options with the pharmacists (if they have not received GEMTESA before leaving the pharmacy)
Sample prescription.

But wait, there’s more!

GEMTESA demonstrated statistically significant reduction
of all 3 key OAB symptoms* vs placebo at 12 weeks—including urgency1,2†

See how GEMTESA may help your patients in long-term care with OAB

Learn more

*The 3 key symptoms of OAB are urgency, micturition frequency, and urge urinary incontinence (UUI)/leakage.2

†The efficacy of GEMTESA was evaluated in a pivotal 12-week, double-blind, randomized, placebo- and active-controlled trial in patients with OAB (UUI, urgency, and urinary frequency). For study entry, patients had to have symptoms of OAB for at least 3 months with an average of 8 or more micturitions per day and at least 1 UUI per day, or an average of 8 or more micturitions per day and an average of at least 3 urgency episodes per day. A total of 1515 patients received at least 1 daily dose of placebo (n=540), GEMTESA 75 mg (n=545), or an active-control treatment (n=430). The majority of patients were Caucasian (78%) and female (85%) with a mean age of 60 (range 18 to 93) years.1

 

References: 1. GEMTESA. Prescribing Information. Marlborough, MA; Sumitomo Pharma America; 2023. 2. Edmondson SD, Zhu C, Kar NF, et al. Discovery of vibegron: a potent and selective β3 adrenergic receptor agonist for the treatment of overactive bladder. J Med Chem. 2016;59(2):609-623. doi:10.1021/acs.jmedchem.5b01372

Back to Top